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Background: Atazanavir and lopinavir represent the main HIV protease inhibitors recommended in pregnancy,
but comparative data in pregnant women are limited.
Methods: Women from a national observational study, exposed in pregnancy to either atazanavir or lopinavir,
were compared for glucose and lipid profiles, liver function tests, CD4 count, HIV RNA and main pregnancy out-
comes. Statistical methods included univariate and multivariable analyses.
Results: The study population included 428 pregnancies (lopinavir, 322; atazanavir, 106). The lopinavir groupwas
characterized by higher rates of HIV diagnosis in pregnancy and treatment indication for maternal health, lower
CD4 counts, higher HIV RNA levels, less frequent antiretroviral treatment at conception and shorter duration of
drug exposure during pregnancy. No differences in pregnancy outcomes, glucose metabolism and weight gain
were observed. The two groups also showed in amultivariable analysis similar odds for detectable HIV RNA in the
third trimester (adjusted OR 0.85, 95% CI 0.35–2.10, P¼0.730). Total lipid levels were significantly higher in the
lopinavir group (median values in the third trimester 239 versus 221 mg/dL for total cholesterol and 226 versus
181 mg/dL for triglycerides; P,0.001 for both comparisons) and bilirubin levels were significantly higher in the
atazanavir group (1.53 versus 0.46 mg/dL, P,0.001).
Conclusions: In this observational study atazanavir and lopinavir showed similar safety and activity in pregnancy,
with no differences in themain pregnancy outcomes. Atazanavir usewas associatedwith a better lipid profile and
with higher bilirubin levels. Overall, the study findings confirm that these two HIV protease inhibitors represent
equally valid alternative options.
Keywords: pre-term delivery, HIV RNA, cholesterol, triglycerides, bilirubin
Introduction
The significant progress of antiretroviral treatment in HIV infection
has led to a remarkable decline in HIV-associated morbidity and
mortality and to a dramatic reduction in mother-to-child
transmission of HIV.1 –3 Although growing evidence indicates
that antiretroviral treatment in pregnancy has overall a very
favourable risk–benefit profile, it is important to maintain moni-
toring of the safety and efficacy of individual drugs and drug
classes in order to optimize treatment recommendations.
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Protease inhibitors are commonly used in pregnancy, usually in
combination with nucleoside or nucleotide reverse transcriptase
inhibitors, with no apparent increase in the risk of birth defects
associated with their use.4 There are, however, for this class of
drugs some concerns regarding metabolic disturbances and pre-
term delivery5 –7 that require further evaluation. Based on the
experience of use and available information, current guidelines
for HIV treatment usually recommend atazanavir and lopinavir
as preferred HIV protease inhibitors in pregnancy.8 – 10 Despite
these recommendations, there is limited comparative information
in pregnancy for these two drugs; in particular, it is not known to
what extent the bettermetabolic profile and higher impact on bili-
rubin levels shown by atazanavir in clinical and observational
studies is also maintained in pregnancy, in which hormonal
changes induce significant metabolic changes. There is also no
comparative information on the efficacy of these two drugs in
obtaining an undetectable HIV viral load at the end of pregnancy,
and, in general, on their impact on pregnancy outcomes. In order
to further explore this issue, we studied a national cohort of preg-
nant women with HIV who had had antenatal exposure to either
lopinavir or atazanavir, evaluating glucose and plasma lipid pro-
files, HIV viral load, bilirubin levels and liver function test abnor-
malities, and some major pregnancy outcomes, such as
pre-term delivery, low birthweight, non-elective Caesarean sec-
tion and neonatal gestational age-adjusted birthweight Z-score.
Patients and methods
Data from the Italian National Program on Surveillance on Antiretroviral
Treatment in Pregnancy were used. This is a national observational
study of pregnant women with HIV established in Italy in 2001, reflecting
routine clinical care. Only HIV-positive pregnant women are included and
no specific guidance is given in terms of treatment of HIV infection or
prophylaxis for mother-to-child transmission, which are decided by the
treating physician. Laboratory and clinical data are collected from hospital
records of the obstetrics, infectious diseases and paediatrics departments
after the women have given consent. Information on smoking and sub-
stance use (heroin, cocaine or methadone) and on the HIV status of the
current partner is based on the woman’s subjective report. Information
and measurements are collected at routine visits performed during preg-
nancy (with no restrictions on gestational age at entry into prenatal care),
at delivery, during the post-partum period and during follow-up of
mothers and newborns for up to 18 months. Voluntary pregnancy termi-
nations and miscarriages are reported only by some of the participating
centres. The time of HIV diagnosis (reported in months) is calculated
using the date difference between HIV diagnosis and the last menstrual
period. Gestational age at birth is determined on the basis of the last men-
strual period, ultrasound biometry or both. Pre-term delivery is defined as
delivery before 37 completed weeks of gestation, and low and very low
birthweight by values below 2500 and 1500 g, respectively. Caesarean
section is considered elective if performed before the rupture of mem-
branes and the onset of labour and non-elective if performed after the rup-
ture of membranes or onset of labour, or both. Information on newborns
includes gender, birthweight, gestational age, Apgar score, HIV status and
presence of congenital or functional/biochemical abnormalities. Informed
consent is required for all enrolled women, using a patient information
sheet that has received approval by the competent ethics committee
(National Institute for Infectious Diseases L. Spallanzani, Rome).
All the results reported here are based on data extracted from the gen-
eral database on 10 June 2013, and refer to pregnancies that occurred
between December 2001 and June 2013. For the present analysis, we con-
sidered all pregnancies with either atazanavir or lopinavir exposure ending
in live births, excludingmiscarriages, terminations and intrauterine deaths
or stillbirths. The time of initiation of treatment in pregnancy was
described in weeks of gestation, and women on antiretroviral treatment
at the last menstrual period were considered to be on treatment at con-
ception. In order to focus on metabolic and efficacy differences between
the two drugs in women on treatment in late pregnancy, the main out-
comes evaluated were glucose and lipid profiles and viral load in the
third trimester. Other laboratory and clinical outcomes were represented
by bilirubin levels and liver function test abnormalities, defined by one or
more of the following: serum alanine or aspartate aminotransferase levels
.60 U/L; serum bilirubin values.1.8 mg/dL; and serum g-glutamyl trans-
ferase levels.150 U/L. The outcome of pregnancywas evaluated through
rates of non-elective Caesarean section and pre-term delivery. Neonatal
outcomes included low and very low birthweight, gender- and gestational
age-adjusted Z-scores, and percentiles for birthweight (calculated accord-
ing to national reference standards).11 HIV transmission and infant mor-
tality were not analysed because of limited event rates, and birth defects
data by antiretroviral treatment were also not analysed because of recent
published work on this issue.12
In order to be eligible for the comparison, the following criteria were
required: available information on gestation week of delivery and on
time of start and end of treatment; start of lopinavir and atazanavir no
later than 22 weeks of pregnancy; and combination antiretroviral treat-
ment during the third trimester, continued until delivery, and no switch
to or from different protease inhibitors during pregnancy. Usual dosages
for lopinavir and atazanavir were 400 mg twice daily with 100 mg ritonavir
twice daily and 300 mg once daily with ritonavir 100 mg daily.
Demographic data were summarized with descriptive statistics.
Quantitative data between women with atazanavir or lopinavir exposure
were compared using the Mann–Whitney U-test. Categorical data were
compared using the x2 test or the Fisher test, as appropriate.Where neces-
sary, in order to adjust for potential confounders, the associations found in
univariate analyses were evaluated in multivariable forward conditional
logistic regression models (which allowed only variables significant at a
level of 0.05 to enter the final model) and were expressed as adjusted
ORs and 95% CIs. For all the analyses, P values ,0.05 were considered
statistically significant. The analyses were performed using SPSS software
version 20.0 (IBM, Somers, NY, USA).
Ethics approval
Ethics approval was obtained on 28 September 2001 from the Ethics
Committee of the Istituto Nazionale per la Malattie Infettive Lazzaro
Spallanzani in Rome (Deliberation no. 578).
Results
Overall, among 3166 pregnancies with an initial registration as of
10 June 2013, 2071 (65.4%) had information on pregnancy out-
come (categorized as live birth, termination, miscarriage or intra-
uterine death). Following exclusion of pregnancies not ending in a
live birth (n¼286), not exposed to either lopinavir or atazanavir
(n¼1108) or exposed to both drugs during pregnancy (n¼37),
640 pregnancies had exposure to either lopinavir (n¼509) or ata-
zanavir (n¼131). Among these pregnancies, 54 (lopinavir 48, ata-
zanavir 6) also had exposure to other HIV protease inhibitors in
pregnancy, 36 (lopinavir 31, atazanavir 5) had missing informa-
tion on time of delivery or timing of treatment in pregnancy,
91 (lopinavir 81, atazanavir 10) had a late start (.22 weeks) of
lopinavir or atazanavir in pregnancy and 31 (lopinavir 27, atazana-
vir, 4) did not continue lopinavir or atazanavir until delivery.
Following exclusion of these cases, the final analysis was based
on 428 pregnancies (lopinavir 322, atazanavir 106) and 433 live
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births (lopinavir 325, atazanavir 108). The case selection process is
summarized in Figure 1.
The main maternal characteristics of the population studied
are reported in Table 1. The two groups had overall similar demo-
graphic and clinical characteristics, but women in the lopinavir
group were more commonly antiretroviral naive and diagnosed
with HIV in pregnancy, and had a lower CD4 cell count and
more commonly had an indication for treatment for their own
health (i.e. not only for prevention of mother-to-child transmis-
sion). Duration of exposure during pregnancy was also lower for
this group, with less frequent ongoing antiretroviral treatment
at conception and a higher rate of discontinuous treatment during
pregnancy (Table 1). Both groups had a good immunological
status (median CD4 cell count 521 cells/mm3 for atazanavir and
474 cells/mm3 for lopinavir) and a very infrequent history of past
clinical AIDS-defining events (8.6% and 5.7%, respectively). At
delivery, 101 women in the atazanavir group (95.3%) and 317
women in the lopinavir group (98.4%) were on treatment with
at least two other drugs (P¼0.07), usually (98.1% for atazanavir
and 97.8% for lopinavir) nucleoside reverse transcriptase
inhibitors.
Potential metabolic differences between the two drugs were
analysed by assessing weight gain, glucose metabolism and
lipid profile in the third trimester of pregnancy. Occurrence of glu-
cose metabolism abnormalities in pregnancy had similarly fre-
quency (atazanavir 7.5%, lopinavir 5.3%; OR¼1.46, 95% CI
0.61–3.50, P¼0.388), and no significant differences between the
two treatment groups were observed in weight gain during preg-
nancy, insulin levels and homeostasis model of assessment–
insulin resistance (HOMA–IR) values, available for a small sub-
group of women (Table 2). Conversely, lipid metabolism appeared
to be differently influenced by the two drugs, with atazanavir use
associated with lower triglyceride and total cholesterol values in
the third trimester and with less pronounced increases from the
first to the third trimester for these two parameters. No significant
differences between the two groupswere observed for high-density
lipoprotein (HDL)- and low-density lipoprotein (LDL)-cholesterol and
for the total cholesterol/HDL-cholesterol ratio (Table 2).
Pregnancies reported as of 10 June 2013 = 3166 
Excluded: lost to follow-up, ongoing pregnancy,
reporting delay = 1095
Pregnancies with known outcome = 2071
Excluded: 
no ATV or LPV  in pregnancy = 1108
both ATV and LPV in pregnancy = 37
Excluded: miscarriages, terminations, intrauterine
deaths, stillbirths = 286
Excluded:
also exposed to other PIs in pregnancy = 54
unknown time of delivery/time of treatment = 36 
ATV or LPV started after 22 weeks = 91
ATV or LPV stopped before delivery = 31
ATV or LPV started before 22 weeks of pregnancy, 
Analysed:
on treatment at delivery, pregnancy ending in live
births = 428 (433 live births)
Figure 1. Flow chart of cases eligible for the analysis. ATV, atazanavir; LPV, lopinavir; PIs, protease inhibitors.
Treatment profile of atazanavir and lopinavir in pregnancy
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With respect to pregnancy outcomes, the median duration of
pregnancy in the entire group (n¼428) was 38 weeks (IQR 37.0–
38.0), with a pre-term delivery rate of 20.8% (n¼89/428). The
most common mode of delivery was elective Caesarean section
(n¼337/425, 79.3%), followed by non-elective Caesarean section
(n¼76/425, 17.9%) and vaginal delivery, which involved only
2.6% of the women (n¼11). Median birthweight was 2885 g
(IQR 2542–3185) and rates of low (,2500 g) and very low birth-
weight (,1500 g) were 20.5% (n¼83/405) and 1.0% (n¼4/405),
respectively. Complications of delivery, most commonly repre-
sented by surgical wound infections and fever, involved 4.5% of
women (n¼19/418). For all the above outcomes, as also for the
proportions of small (,10th percentile) and large (.90th percent-
ile) by gestational age infants, no significant differences were
found between women exposed to atazanavir and those exposed
to lopinavir (Table 3).
The two protease inhibitors, as expected, had different impacts
on bilirubin values, with consistently higher total bilirubin levels
associated with atazanavir use (median values in the third
trimester 1.53 versus 0.46 mg/dL, P,0.001). This translated
into a higher risk of liver function test abnormalities during preg-
nancy with atazanavir (OR after adjusting for HCV coinfection
2.30, 95%CI1.07–4.91, P¼0.032),which, however, did not neces-
sitate any change in atazanavir treatment. No cases of renal lithi-
asis were reported in pregnant women receiving atazanavir, with
one case reported in the lopinavir group.
Finally, given the significant (P,0.05 in univariate analyses)
imbalance between the two groups in some variables relevant
for the achievement of an undetectable viral load at the end
of pregnancy, we evaluated the predictors of detectable
end-of-pregnancy HIV RNA in a multivariable logistic regression
model that adjusted for pregnancy week of start of treatment,
first-trimester CD4 cell count, HIV RNA levels and drug interrup-
tions during pregnancy. These variables were selected based on
their significance in univariate analyses (P,0.05 required for
inclusion), causal relevance for the outcome and potential re-
dundancy. The multivariate analysis showed that, after adjust-
ment for covariates, the presence of detectable HIV RNA in late
Table 1. Characteristics of pregnant women in the two treatment groups
No. with available information
Median (IQR) or percentage with the
characteristic
P valueatazanavir lopinavir atazanavir lopinavir
Age, years (n¼427) 106 321 34 (30–37) 32 (29–36) 0.058a
Body mass index, kg/m2 (n¼304) 86 218 23.1 (20.2–26.2) 22.3 (20.3–25.2) 0.228a
Time between HIV diagnosis and pregnancy,
months (n¼422)
105 317 69 (23–143) 56 (5–109) 0.026a
Pregnancy week of start of ARV (n¼428) 106 322 1 (1–14) 12 (1–16) <0.001a
CD4 cell count, cells/mm3b (n¼320) 90 230 456 (363–594) 406 (279–572) 0.048a
HIV RNA, log10 copies/mL
b (n¼299) 81 218 1.70 (1.60–3.10) 3.00 (1.70–4.20) <0.001a
Exposure to atazanavir or lopinavir in
pregnancy, weeks (n¼428)
106 322 35 (24–37) 26 (21–36) <0.001a
Twin pregnancy (n¼428) 106 322 1.9 0.9 0.362c
At least one previous pregnancy (n¼426) 106 320 74.5 71.6 0.554c
African ethnicity (n¼423) 106 317 37.7 34.4 0.532c
History of intravenous drug use (n¼423) 105 318 6.7 5.0 0.522c
Smoking .10 cigarettes/day (n¼384) 100 284 15.0 9.9 0.161c
Recent substance used (n¼413) 104 309 4.8 3.6 0.568c
Diagnosis of HIV in current pregnancy (n¼422) 105 317 13.3 23.3 0.029c
HBV coinfection (n¼381) 92 289 7.6 9.3 0.611c
HCV coinfection (n¼414) 102 312 11.8 11.2 0.880c
CD4 count ,200 cells/mm3b (n¼320) 90 230 8.9 10.0 0.763c
History of AIDS-defining events (n¼421) 105 316 8.6 5.7 0.297c
Indication for ARV for their own healthe (n¼400) 104 296 7.7 20.6 0.003c
Antiretroviral naive at start of pregnancy (n¼423) 104 319 20.2 34.2 0.007c
On ARV at conception (n¼422) 106 316 69.8 50.2 0.001c
No interruption of atazanavir or lopinavir treatment
during pregnancy (n¼428)
106 322 93.4 84.8 0.023c
ARV, antiretroviral therapy.
Bold is used for P values ,0.05.
aMann–Whitney U-test.
bFirst trimester.
cx2 test.
dOpiates, benzodiazepines or cocaine.
eARV indicated for maternal health and not only for prevention of mother-to-child transmission.
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pregnancy was not significantly associated with the treatment
received during pregnancy (adjusted atazanavir/lopinavir OR for
HIV RNA .50 copies/mL 0.85, 95% CI 0.35–2.10, P¼0.730), but
appeared to be independently associated with low CD4 counts,
drug interruptions during pregnancy and increasing HIV RNA
levels at the start of pregnancy (Table 4).
Discussion
Current guidelines for pregnant womenwith HIV concur in recom-
mending either lopinavir or atazanavir (both with low-dose
ritonavir) as the preferred protease inhibitor for use in preg-
nancy.8–10 The present analysis provides some comparative infor-
mation from an observational national study of pregnant women
with HIV, based on more than 400 pregnancies exposed. The pro-
portion of evaluable cases reflects themore common use and lar-
ger experience with lopinavir compared with the more recently
introduced atazanavir.4,13 Despite the limits of a non-randomized
design, which are, however, common to studies and registries of
HIV and pregnancy, this study adds new information that might
be of interest. A reassuring finding is that the rates of all the
main pregnancy outcomes were substantially similar for lopinavir
Table 2. Metabolic indexes in the third trimester of pregnancy
No. with available
information in
each group Median (IQR)
P valueatazanavir lopinavir atazanavir lopinavir
Weight increase during pregnancy (kg) (n¼299) 84 215 11 (8–15) 11 (8–14) 0.537
Fasting plasma glucose (mg/dL) (n¼367) 94 273 75 (68–82) 72 (67–78) 0.060
Fasting insulin (mU/mL) (n¼60) 13 47 9.9 (6.8–21.2) 9.2 (5.91–11.9) 0.311
HOMA–IRa (n¼57) 12 45 1.75 (1.21–4.10) 1.61 (0.95–2.28) 0.347
Plasma triglycerides (mg/dL), third trimester (n¼286) 74 212 181 (142–236) 226 (182–309) <0.001
Plasma total cholesterol (mg/dL), third trimester (n¼287) 75 212 221 (194–250) 239 (201–272) <0.001
Plasma HDL-cholesterol (mg/dL), third trimester (n¼213) 59 154 64 (57–73) 65 (56–75) 0.629
Plasma LDL-cholesterol (mg/dL), third trimester (n¼145) 37 108 115 (90–145) 124 (97–154) 0.404
Total cholesterol/HDL-cholesterol ratio (n¼212) 59 153 3.5 (2.9–4.0) 3.5 (3.0–4.4) 0.317
Plasma triglycerides (mg/dL), increase between first and third
trimesters (n¼212)
63 149 84 (60–133) 130 (76–184) 0.002
Plasma total cholesterol (mg/dL), increase between first and third
trimesters (n¼209)
64 145 54 (24–74) 68 (33–99) 0.033
Plasma HDL-cholesterol (mg/dL), increase between first and third
trimesters (n¼149)
48 101 12 (21.5–22.7) 10 (2–18.5) 0.624
Plasma LDL-cholesterol (mg/dL), increase between first and third
trimesters (n¼98)
30 68 29 (3.2–53) 26 (2.2–55.7) 0.732
Bold is used for P values ,0.05.
aCalculated as fasting insulin (in mU/mL)× fasting glucose (in mmol/L)/22.5.
Table 3. Main pregnancy outcomes in mothers exposed to atazanavir or lopinavir
Outcomes
Atazanavir Lopinavir
ORa OR 95% CI P valuen/N % n/N %
Non-elective Caesarean section (n¼413) 15/103 14.6 61/310 19.7 0.70 0.38–1.29 0.248
Complications of deliveryb (n¼418) 7/105 6.7 12/313 3.8 1.79 0.69–4.68 0.228
Preterm delivery (n¼428) 20/106 18.9 69/322 21.4 0.85 0.49–1.48 0.573
Low birthweight (,2500 g) (n¼405; twins included) 21/103 20.4 62/302 20.5 0.99 0.57–1.73 0.976
Very low birthweight (,1500 g) (n¼405; twins included) 3/103 2.9 1/302 0.3 9.03 0.93–87.6 0.058
Undetectable (,50 copies/mL) HIV-RNA in third trimester (n¼346) 78/90 86.7 176/256 68.8 2.95 1.52–5.73 0.001
Small by gestational age (,10th percentile)32 (n¼391, singletons only) 13/100 13.0 36/291 12.4 1.06 0.54–2.01 0.870
Large by gestational age (.90th percentile) (n¼391, singletons only) 4/100 4.0 29/291 10.0 0.38 0.13–1.10 0.074
Bold is used for P values ,0.05.
aReference category¼atazanavir.
bUsually represented by surgical wound infections and fever.
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and atazanavir. This is particularly relevant for pre-term delivery,
non-elective Caesarean section and low birthweight, because
such outcomes, and pre-termdelivery in particular, are associated
with significant neonatalmorbidity.14 An analysis of HIV transmis-
sion and neonatal mortality was not performed because both
these outcomes represent infrequent events (,2%) that require
very large samples for comparative analyses. Study data on
birth defects for the subgroup of pregnancies with first-trimester
exposure12 (roughly half of the cases shown here) were consistent
with reference data from the Antiretroviral Pregnancy Registry,
which indicate for both drugs no major increase in rate of birth
defects for first trimester exposure.4
In terms of virological efficacy, achieving an end-of-pregnancy
undetectable viral load is a key objective of antiretroviral treat-
ment in pregnancy, given the major role of HIV RNA plasma levels
in determining HIV vertical transmission.15,16 In this context, fol-
lowing adjustment for confounders (pregnancy week of start of
treatment, first-trimester CD4 cell count, HIV RNA levels and
drug interruptions during pregnancy), the two drugs were equally
effective in determining an undetectable viral load at the end
of pregnancy, suggesting comparable virological efficacy in
pregnancy.
Atazanavir confirmed its role in inducing hyperbilirubinaemia;
this occurrence was responsible for a significantly higher fre-
quency of liver function test abnormalities in pregnancy, which,
however, had no impact on continuation of atazanavir, further
supporting the hypothesis that the clinical significance of
atazanavir-induced hyperbilirubinaemia is generally limited.17,18
Recent studies have also shown that this occurrence in pregnancy
seems to have no adverse consequence in the newborn.19
It is as yet uncertain whether protease inhibitors further
increase the risk of glucose metabolism abnormalities in preg-
nancy, because published studies were not always consistent,
and cofactors such as ethnic origin and body mass index may
playa confounding role.20–25Our study provides new comparative
information, showing for atazanavir and lopinavir a similar impact
on glucose metabolism. It is important to note that this conclu-
sion is also based on fasting insulin and HOMA–IR data collected
in a subgroup of women. It is also important to underline that the
rate of glucose metabolism abnormalities observed was well
below the rates observed in other studies based on populations
with different demographic and clinical characteristics.25 Finally,
the identical weight gain in pregnancy with lopinavir or atazanavir
is reassuring in terms of potential complications related to exces-
sive weight gain.
Apart from hyperbilirubinaemia, the only significant metabolic
difference between the two drugs was represented by a different
impact on triglyceride and cholesterol levels, which were signifi-
cantly lower with atazanavir. This indicates that the difference
in lipid profile between the two drugs observed in clinical trials26,27
is maintained also in the particular context of pregnancy, where
lipid values are subject to a significant and progressive increase
from the first to the third trimester, with remarkable rates of
hypertriglyceridaemia and hypercholesterolaemia.28 Although
the clinical consequences of lipid changes in pregnancy may
be limited, early hypertriglyceridaemia has been associated
with subsequent occurrence of gestational diabetes and pre-
eclampsia,29,30 and might contribute to the development of
fetal macrosomia.31 Interestingly, in this respect we observed a
higher proportion of large-by-gestational-age infants (.90th per-
centile) with lopinavir (10.0% versus 4.0%), but the differencewith
atazanavir was not statistically significant. Overall, atazanavir
might represent a preferable choice in particular situations if
there is an indication that suggests clinical benefits for maintain-
ing lower levels of triglycerides and cholesterol during pregnancy.
In terms of strengths and limitations, our study has the advan-
tage of providing new information on a particular population com-
monly excluded from clinical trials, with a sample size of more
than 400 cases. Wewere also able to analyse an array of different
measures that included maternal and infant outcomes,
HIV-related parameters and metabolic indexes, allowing a
broad evaluation of the profiles of the two drugs in pregnancy.
The limitations of this study include a non-randomized attribution
of treatment and a potential selection bias due to the exclusion of
cases who switched to and from these two protease inhibitors in
pregnancy. However, randomized studies are very difficult to per-
form in pregnancy, and the reason for switching during pregnancy
may represent a combination of toxicity, confidence in older drugs
and alignment with international HIV perinatal guidelines. Other
study limitations include availability of some measures (insulin
and HOMA–IR) only for a minority of cases and imbalance
between the two groups for some characteristics, which was,
however, corrected in a multivariable analysis. Finally, the sample
size did not have enough statistical power to detect significant dif-
ferences in more infrequent outcomes, such as delivery complica-
tions and large-by-gestational-age infants.
Table 4. Multivariable analysis of predictors of detectable (.50 copies/mL) HIV RNA in the third trimester
AOR AOR 95% CI P value
Treatment group (reference¼ atazanavir) 0.85 0.35–2.10 0.730
Any interruption of atazanavir or lopinavir during pregnancy 3.52 1.29–9.61 0.014
CD4 cell count ,200 cells/mm3 at first trimester 5.90 2.03–17.1 0.001
HIV RNA viral load at first trimester (per additional log) 2.00 1.43–2.80 <0.001
Pregnancy week of start of antiretroviral treatment (per additional week) 1.01 0.95–1.08 0.637
AOR, adjusted OR.
Bold is used for P values ,0.05.
The multivariable analysis was performed in order to adjust for significant differences between the two groups in potentially relevant predictors.
Variables were selected for the model based on a significant (,0.05) P value in the univariate analyses of Table 1, causal relevance for the outcome
and potential redundancy/overlapping (i.e. indication to ARV/CD4 count; treatment status at conception/pregnancy week of start of ARV).
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Overall, the study findings show that the two HIVprotease inhi-
bitors currently recommended by HIV perinatal guidelines appear
to have similar safety and activity in pregnancy, likely representing
equally valid alternative options. Physicians prescribing lopinavir
or atazanavir to pregnant women should be aware of the different
risks of hyperlipidaemia and hyperbilirubinaemia, respectively, for
the two drugs, and evaluate their potential clinical implications.
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